Browsing Tag
Biofrontera Inc.
3 posts
Will pharmacokinetics data support 240 cm2 treatment fields for Ameluz?
Biofrontera Inc. advances Ameluz toward 240 cm2 FDA review. Explore the regulatory, financial, and competitive stakes in dermatology markets.
Is photodynamic therapy ready to move beyond facial use in actinic keratosis care?
Biofrontera Inc.’s Phase 3 Ameluz data extend photodynamic therapy beyond the face. Find out how this could reshape field treatment decisions.
Biofrontera reaches key clinical milestone with database locks across two ongoing studies
Find out why Biofrontera Inc.’s database locks for two clinical studies strengthen regulatory readiness and advance key data milestones.